Home » Topics » Inflammatory, BioWorld Science

Inflammatory, BioWorld Science
RSS

Cardiac Hsl gene knockdown provides model of hypoxia tolerance

Dec. 1, 2017

Bristol-Myers Squibb initiates phase I trial of BMS-986235 in healthy subjects

Nov. 24, 2017

Spingotec Therapeutics divulges DPP3 inhibitors

Nov. 22, 2017

First-in-human results provided for TR-Pharm's anti-interleukin-1 biologic RPH-104

Nov. 15, 2017

New yohimbine analogues synthesized at the University of Florida

Nov. 15, 2017

Novel NLRP3 inflammasome inhibitors presented by IFM Therapeutics

Nov. 3, 2017

Novel leukotriene A-4 hydrolase inhibitors identified at Novartis

Oct. 31, 2017

Allergan presents new fMet-Leu-Phe receptor modulators

Oct. 30, 2017

University of Texas, Immune Sensor divulge new cyclic GMP-AMP synthase inhibitors

Oct. 19, 2017

Blade Therapeutics patents novel calpain inhibitors

Oct. 4, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...